BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib-Reference-Cited by-同舟云学术

BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib

Published:2015-03 Issue:3 Volume:1852 Page:462-472
ISSN:0925-4439
Container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Author:

Faraoni Isabella,Compagnone Mirco,Lavorgna Serena,Angelini Daniela Francesca,Cencioni Maria Teresa,Piras Eleonora,Panetta Paola,Ottone Tiziana,Dolci Susanna,Venditti Adriano,Graziani Grazia,Lo-Coco Francesco

Funder

Associazione Italiana per la Ricerca sul Cancro” (AIRC)

Publisher

Elsevier BV

Subject

Molecular Biology,Molecular Medicine

Reference48 articles.

1. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet;Döhner;Blood,2010

2. Acute myeloid leukemia;O'Donnell;J. Natl. Compr. Cancer Netw.,2012

3. Toward a unified nomenclature for mammalian ADP-ribosyltransferases;Hottiger;Trends Biochem. Sci.,2010

4. PARPs and the DNA damage response;Sousa;Carcinogenesis,2012

5. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy;Farmer;Nature,2005

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the DNA damage response in hematological malignancies;Frontiers in Oncology;2024-01-29

2. Studying the DNA damage response pathway in hematopoietic canine cancer cell lines, a necessary step for finding targets to generate new therapies to treat cancer in dogs;Frontiers in Veterinary Science;2023-08-16

3. Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review;Cancers;2023-02-21

4. Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance;EMBO Molecular Medicine;2023-01-18

5. In the Pipeline: Emerging Therapy for Acute Myeloid Leukaemia;Pathogenesis and Treatment of Leukemia;2023